- Home
- JLL vs EXEL Comparison
JLL vs EXEL Comparison
Compare JLL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- EXEL
- Stock Information
- Founded
- JLL 1997
- EXEL 1994
- Country
- JLL United States
- EXEL United States
- Employees
- JLL N/A
- EXEL N/A
- Industry
- JLL Real Estate
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JLL Finance
- EXEL Health Care
- Exchange
- JLL Nasdaq
- EXEL Nasdaq
- Market Cap
- JLL 10.4B
- EXEL 9.8B
- IPO Year
- JLL 1997
- EXEL 2000
- Fundamental
- Price
- JLL $229.64
- EXEL $36.17
- Analyst Decision
- JLL Strong Buy
- EXEL Buy
- Analyst Count
- JLL 6
- EXEL 18
- Target Price
- JLL $315.83
- EXEL $37.59
- AVG Volume (30 Days)
- JLL 371.8K
- EXEL 2.2M
- Earning Date
- JLL 05-07-2025
- EXEL 05-13-2025
- Dividend Yield
- JLL N/A
- EXEL N/A
- EPS Growth
- JLL 78.40
- EXEL 170.77
- EPS
- JLL 11.07
- EXEL 1.76
- Revenue
- JLL $24,054,800,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- JLL $9.68
- EXEL $5.78
- Revenue Next Year
- JLL $7.67
- EXEL $10.94
- P/E Ratio
- JLL $20.77
- EXEL $20.64
- Revenue Growth
- JLL 13.63
- EXEL 18.50
- 52 Week Low
- JLL $186.50
- EXEL $20.14
- 52 Week High
- JLL $288.50
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- JLL 50.82
- EXEL 43.89
- Support Level
- JLL $220.00
- EXEL $34.90
- Resistance Level
- JLL $232.82
- EXEL $40.26
- Average True Range (ATR)
- JLL 6.69
- EXEL 1.21
- MACD
- JLL 2.05
- EXEL -0.19
- Stochastic Oscillator
- JLL 73.56
- EXEL 23.69
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.